参考文献/References:
[1]Weiner LM. An overview of monoclonal antibody therapy of cancer.Semin Oncol, 1999, 26(4 Suppl 12):S41-S50.
[2]甄永苏. 肿瘤的靶向治疗.国外医学?肿瘤学,2002, 29(5):323-326.
[3]Folkman J. What is the evidence that tumors are angiogenesis dependent.J Natl Cancer Inst,1990,82(1):4-6.
[4]Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL as first line therapy in subjects with metastatic CRC.Proc Am Soc Clin Oncol,2003,22:3646.
[5]李云春, 肖荣贵. 放射性核素诊断和治疗肿瘤的新型载体:Endostatin . 同位素, 2001,14(1):50-53.
[6]Steward WP. Marimastat (BB2516): current status of development.Cancer Chemother Pharmacol, 1999, 43(Suppl):S56-S60.
[7]Steward WP, Thomas AL. Maristat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs, 2000,9:2913-2922.
[8]Vose JM, Link BK, Grossbard ML,et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hoddgkins lymphoma. J Clin Oncol, 2001,19:389-397.
[9]Coiffier B. Rituximab in the Treatment of Diffuse Large B-Cell Lymphoma. Semin Oncol, 2002,29(1 Suppl 2):S30-S35.
[10]Olayioye MA, Neve RM, Lane HA, et al. The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000,19:3159-3167.
[11]Wordbun JR. The epidermal growth factor and its inhibitor in cancer therapy. Pharmacol Therapy, 1999,82:241-250.
[12]Cunningham D, Humblett Y, Siena S, et al.Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR) positive, irinotecan refractory metastatic colorectal cancer(MCRC). Proc Am Soc Clin Oncol, 2003,22:252.
[13]Tabernero J, Salazar R, Casado E, et al. Targeted therapy in advanced colon cancer: the role of new therapy. Annals of Oncology, 2004,15(Suppl 4):S55-S62.
[14]Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2.N Engrl J Med,2001,344:783-792.
[15]Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs,2000,60(Suppl 1):S15-S23;(discussion 4):1-12.
[16]Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839(Iressa) in advanced non-small cell lung cancer(NSCLC) patients who had failed platinum-and docetaxel-based regimens(IDRAL2). J Clin Oncol, 2002, 21: 292.
[17]Takano T, Ohe Y, Kusumoto M,et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gifitinib. Lung Cancer ,2004,45:93-104.
[18]Kaneda H, Tamura K, Kurata T, et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer,2004,46:247-254.
[19]Gatzemeier U, Pluzanska A, Szczesna A, et al. Result of a phase III trial of erlotinib(OSI-774) combined with cisplatin and gemcitabine(GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Onco, 2004, 22:617.
[20]Herbst RS, Prager D, Hermann R, et al. TRIBUTE-A phase III trial of erlotinib HCI(OSI-774) combined with carboplatin and paclitaxel(CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Onco, 2004, 22:617.
[21]Deininge MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR/ABL-positive cells. Blood, 1997, 90:3691-3698.
[22]O'Brian SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose Cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 2003, 348:994-1004.
[23]Sakurai S, Fukasawa T, Chong JM, et al. Embryonic form of smooth muscle myosin heavy chain (Semb/MCH-B) in gastrointestinal stromal tumor and interstinal cells of Cajal. Am J Pathol, 1999, 154(1):23-28.
[24]Verweij J, Gasali PG, Zalcber J, et al. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors(GIST): Interim results of a randomized phase III trial from EROTC-STBSG, ISG and AGITG.. Proc Am Soc Clin Oncol, 2003, 22: 814.
[25]Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate(STI571) for GIST: Intergroups S0033 early results. Proc Am Soc Clin Oncol, 2003, 22: 814.
[26]Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumor by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res, 1999, 59:1236-1243.
[27]Lode HN, Reisfeld RA, Handgretinger R, et al. Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I) 1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res, 1998, 58:2925-2928.
[28]甄永苏,邵荣光,江敏,等. 抗癌抗生素C1027与单克隆抗体偶联物的抗肿瘤作用. 中国肿瘤生物治疗杂志,1994, 2(2):94-98.